Outlook Therapeutics, Inc.
OTLK
$0.64
$0.000.53%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
9/9/2026
-
MarketBeat
8/27/2026
-
TipRanks: TheFly
8/27/2026
-
Globe Newswire
JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs
8/27/2026
-
ACCESS Newswire
8/27/2026
-
Globe Newswire
8/25/2026
-
TipRanks
8/21/2026
-
MarketBeat
8/20/2026
-
MarketBeat
8/17/2026
-
TipRanks
8/17/2026
-
MarketBeat
8/17/2026
-
Zacks Investment Research
8/17/2026
-
The Cerbat Gem
8/17/2026
-
TipRanks: TheFly
8/15/2026
-
The Cerbat Gem
8/15/2026
-
MarketBeat
8/15/2026
-
MarketBeat
8/15/2026
-
Simply Wall St
8/15/2026
-
MarketBeat
8/15/2026
-
SeekingAlpha
8/15/2026
-
MarketBeat
8/14/2026
-
Seeking Alpha - Healthcare
8/14/2026
-
Seeking Alpha: Transcripts
8/14/2026
-
SeekingAlpha
8/14/2026
-
MarketBeat
8/14/2026
-
Benzinga
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Tuesday, August 18, 2026
Period Date
Tuesday, June 30, 2026
Next Filing
Week of Dec 14 and 18 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
609 619 3990
Address
111 S. Wood Avenue
Unit #100
Iselin, NJ 08830
Unit #100
Iselin, NJ 08830
Country
Year Founded
Business Description
Sector
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product...
more